Clinical trials: Type 2 Diabetes Mellitus Without Insulin Treatment
Adult Patients With Type 2 Diabetes Uncontrolled on Oral Antidiabetic Drugs
A Study Comparing HR17031 With Insulin Glargine in Patients With Type 2 Diabetes
The aim of this trial is to confirm the efficacy of HR17031 in controlling glycaemia in Chinese subjects with type 2 diabetes mellitus inadequately controlled on oral antidiabetic agents
- Trial name
- NCT06881264
- Testing
- HR17031 injection, insulin glargine
- Where
- China
- Volunteers
- 401 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Type 2 Diabetes Mellitus
Assessment of the Efficacy and Safety of Lixisenatide in Patients With Type 2 Diabetes Insufficiently Controlled With Basal Insulin +/- Metformin
Primary Objective: To assess the effects on glycemic control of lixisenatide in comparison to placebo as an add-on treatment to basal insulin with or without metformin in terms of HbA1c reduction over a period of 24 weeks in…
- Trial name
- NCT01632163
- Testing
- Lixisenatide (AVE0010)
- Where
- 51 sites in China, India and 2 more
- Volunteers
- 447 people
- Sponsor
- Sanofi
Diabetes Mellitus, Type 2
A Research Study to See How Well the New Weekly Medicine IcoSema, Which is a Combination of Insulin Icodec and Semaglutide, Controls Blood Sugar Level in People With Type 2 Diabetes Compared to Insulin Glargine Taken Daily With Insulin Aspart (COMBINE 3)
This study will compare the new medicine IcoSema, which is a combination of insulin icodec and semaglutide, taken once a week, to insulin glargine taken daily with insulin aspart in people with type 2 diabetes.The study will look…
- Trial name
- NCT05013229
- Testing
- IcoSema, Insulin glargine, insulin aspart
- Where
- 182 sites in United States, Czechia and 12 more
- Volunteers
- 679 people
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus, Type 2
Study of Human Regular U-500 Insulin in Adult Participants With Type 2 Diabetes
The main purpose of this study is to compare the effectiveness of Human Regular U-500 Insulin three times a day versus twice a day.
- Trial name
- NCT01774968
- Testing
- Human Regular U-500 Insulin
- Where
- 39 sites in United States, Puerto Rico
- Volunteers
- 325 people
- Sponsor
- Eli Lilly and Company
Diabetes Mellitus, Type 2
GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Basal Insulin +/- Sulfonylurea (GETGOAL-L-ASIA)
The purpose of this study is to evaluate the benefits and risks of lixisenatide (AVE0010), in comparison to placebo, as an add-on treatment to basal insulin with or without sulfonylurea, over a period of 24 weeks of treatment.
- Trial name
- GETGOAL-L-ASIA (NCT00866658)
- Testing
- Lixisenatide (AVE0010), Pen auto-injector, Sulfonylurea
- Where
- 4 sites in Japan, Philippines and 2 more
- Volunteers
- 311 people
- Sponsor
- Sanofi
Diabetes, Diabetes Mellitus, Type 2
The Effect of Insulin Detemir on Blood Glucose Control in Taiwanese Patients With Type 2 Diabetes Failing on OAD
The trial is conducted in Asia. The aim of the trial is to evaluate the effect of insulin detemir on blood glucose control in Taiwanese patients with type 2 diabetes failing on OAD with/without once-daily NPH Insulin treatment.
- Trial name
- NCT00521690
- Testing
- insulin detemir
- Where
- Taiwan
- Volunteers
- 25 people
- Sponsor
- Novo Nordisk A/S
Obesity, Diabetes Mellitus, Type 2
Efficacy, Safety, and Tolerability of Tirzepatide in Real-World Conditions in Paraguay.
This is a prospective cohort study evaluating the efficacy, safety, and tolerability of tirzepatide under real-world conditions in the Paraguayan population.
- Trial name
- REAL-TIRZEPY (NCT07588438)
- Testing
- Tirzepatide (LIPOLESS de Laboratorio de Productos Eticos C.E.I.S.A.)
- Where
- Paraguay
- Volunteers
- 160 people
- Sponsor
- Las Rías Medical Center
Continuous Glucose Monitoring, Type 2 Diabetes
A Study on the Effect of CGM Alone on Glycemic Metrics in Type 2 Diabetes Patients Not Using Insulin, Without Additional Interventions
This study evaluates the effect of using a real-time continuous glucose monitoring (CGM) system on blood sugar control in people with type 2 diabetes who do not use insulin.
- Trial name
- NCT07298850
- Testing
- Continuous glucose monitoring
- Where
- South Korea
- Volunteers
- 120 people
- Sponsor
- Kangbuk Samsung Hospital
Diabetes Mellitus, Type 2
Efficacy and Safety of BI 10773 in Combination With Insulin in Patients With Type 2 Diabetes
The objective of the current study is to investigate the efficacy, safety and tolerability of BI 10773 at two different doses compared to placebo during long term treatment (78 weeks) in combination with basal insulin in patients…
- Trial name
- NCT01011868
- Testing
- BI 10773 low dose, BI 10773 high dose
- Where
- 99 sites in United States, Denmark and 5 more
- Volunteers
- 494 people
- Sponsor
- Boehringer Ingelheim
Type 2 Diabetes Mellitus
Comparison of the Efficacy and Safety of Insulin Glargine/Lixisenatide Fixed Ratio Combination to Insulin Glargine in Patients With Type 2 Diabetes Insufficiently Controlled on Basal Insulin
Primary Objective: To demonstrate the superiority of iGlarLixi (fixed ratio combination of insulin glargine and lixisenatide) to insulin glargine on glycemic control as assessed by glycated hemoglobin A1c (HbA1c) change in…
- Trial name
- Lixilan-L-CN (NCT03798080)
- Testing
- Insulin glargine/Lixisenatide (HOE901/AVE0010), Insulin glargine (HOE901), Metformin
- Where
- 45 sites in China
- Volunteers
- 426 people
- Sponsor
- Sanofi
Diabetes, Diabetes Mellitus, Type 2
Comparison of NN1250 With Insulin Glargine Plus Insulin Aspart With/Without Metformin and With/Without Pioglitazone in Type 2 Diabetes
This trial is conducted in Africa, Asia, Europe, and the United States of America (USA). The aim of this clinical trial is to compare NN1250 (insulin degludec (IDeg)) with insulin glargine (IGlar) plus insulin aspart (IAsp)…
- Trial name
- BEGIN™ (NCT00972283)
- Testing
- insulin degludec, insulin glargine, insulin aspart
- Where
- 136 sites in United States, Bulgaria and 10 more
- Volunteers
- 1,006 people
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus, Type 2
Study Of AVANDAMET® With Or Without Insulin In Type II Diabetes Mellitus Patients. AVANDAMET® is a Registered Trademark of the GSK Group of Companies.
This study was designed to test the safety and efficacy (how well it works) of AVANDAMET in combination with insulin in improving the control of blood sugar when compared with taking insulin on its own.
- Trial name
- NCT00069836
- Testing
- Rosiglitazone/metformin
- Where
- 93 sites in Austria, France and 3 more
- Volunteers
- 272 people
- Sponsor
- GlaxoSmithKline
Diabetes, Diabetes Mellitus, Type 2
Comparison of NN5401 With Biphasic Insulin Aspart 30 in Type 2 Diabetes
This trial is conducted in Asia, Europe and Oceania. The aim of this clinical trial is to compare NN5401 (insulin degludec/insulin aspart) with biphasic insulin aspart 30 in subjects with type 2 diabetes.
- Trial name
- BOOST™ (NCT01009580)
- Testing
- insulin degludec/insulin aspart, biphasic insulin aspart 30
- Where
- 53 sites in Australia, Denmark and 8 more
- Volunteers
- 447 people
- Sponsor
- Novo Nordisk A/S
Diabetes, Diabetes Mellitus, Type 2
Effect of Biphasic Insulin Compared to Biphasic Insulin Combined With Insulin Aspart, With or Without Metformin in Type 2 Diabetes
This trial is conducted in Africa and Middle East. The objective of the study is to compare glycemic control of Biphasic insulin Aspart 30 twice daily with Biphasic insulin Aspart 30 twice daily plus Insulin Aspart, both insulin…
- Trial name
- NCT00282451
- Testing
- biphasic insulin aspart, insulin aspart
- Where
- 4 sites in Egypt, Saudi Arabia
- Volunteers
- 79 people
- Sponsor
- Novo Nordisk A/S
Adult Patients With Type 2 Diabetes
A Trial Comparing HR17031 With Insulin Glargine in Patients With Type 2 Diabetes
To compare the efficacy and safety of HR17031 injection and insulin glargine, including the changes of efficacy indicators such as HbA1c, fasting blood glucose, body weight and safety indicators such as adverse events and…
- Trial name
- NCT06871761
- Testing
- HR17031 injection, insulin glargine
- Where
- China
- Volunteers
- 393 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Type 2 Diabetes Mellitus
A 24-week Open-Label, Phase 3b Trial With a 28-week Extension to Evaluate the Efficacy and Safety of Saxagliptin Co-administered With Dapagliflozin Compared to Insulin Glargine in Subjects withType 2 Diabetes Who Have Glycemic Control on Metformin
This research study of subjects with inadequately controlled type 2 diabetes mellitus (T2DM) will compare the glycemic control (measured by HbA1c) in subjects co-administered saxagliptin and dapagliflozin, in addition to…
- Trial name
- NCT02551874
- Testing
- Saxagliptin, Onglyza, Dapagliflozin, Farxiga, Glargine insulin
- Where
- 40 sites in United States, Czechia and 8 more
- Volunteers
- 650 people
- Sponsor
- AstraZeneca
Type 2 Diabetes Mellitus
Pharmacodynamic Effects of Lixisenatide Compared to Liraglutide in Patients With Type 2 Diabetes Not Adequately Controlled With Insulin Glargine With or Without Metformin
Primary Objective: To investigate the effects of repeated subcutaneous doses of lixisenatide 20 μg once daily (QD) as compared to liraglutide 1.2 mg QD or 1.8 mg QD in reducing post-prandial plasma glucose (PPG) assessed as area…
- Trial name
- NCT01596504
- Testing
- Lixisenatide (AVE0010), Liraglutide, Insulin Glargine
- Where
- 8 sites in Germany
- Volunteers
- 142 people
- Sponsor
- Sanofi
Diabetes Mellitus, Type 2
A Research Study in People With Type 2 Diabetes to Compare Two Types of Insulin: Insulin 287 and Insulin Glargine
This study compares insulin 287 (a possible new medicine) to insulin glargine (a medicine doctors can already prescribe) in people with type 2 diabetes.
- Trial name
- NCT03922750
- Testing
- Insulin icodec, Insulin glargine U100
- Where
- 38 sites in United States, Canada and 3 more
- Volunteers
- 154 people
- Sponsor
- Novo Nordisk A/S
Diabetes, Diabetes Mellitus, Type 2
Efficacy and Safety of a Fixed or a Flexible Supplementary Insulin Therapy in Type 2 Diabetes
This trial is conducted in Europe. This trial aims for a comparison of the efficacy and safety of Insulin Aspart, given in a fixed or in a flexible supplementary insulin therapy, with or without Insulin Detemir plus Metformin, if…
- Trial name
- NCT00274274
- Testing
- insulin detemir, insulin aspart
- Where
- Germany
- Volunteers
- 373 people
- Sponsor
- Novo Nordisk A/S
Diabetes, Type 1, Diabetes, Type 2
Safety of Inhaled Insulin With Type 1 and Type 2 Diabetes
Pulmonary Safety in Diabetics with T/I
- Trial name
- NCT00308737
- Testing
- Technosphere® Insulin Inhalation Powder, Usual Care
- Where
- 176 sites in United States, Canada and 6 more
- Volunteers
- 2,053 people, healthy volunteers welcome
- Sponsor
- Mannkind Corporation